Breaking News Instant updates and real-time market news.

EXEL

Exelixis

$13.18

0.06 (0.46%)

, RHHBY

Roche

$30.54

-0.29 (-0.94%)

04:51
10/07/16
10/07
04:51
10/07/16
04:51

Exelixis announces Genentech presentation of preliminary phase 1b trial results

Exelixis (EXEL) announced that its collaborator Genentech, a member of the Roche Group (RHHBY), will present preliminary results from a phase 1b clinical trial evaluating the safety and clinical activity of the triple combination of cobimetinib, vemurafenib, and atezolizumab in patients with previously untreated BRAF V600 mutation-positive advanced melanoma. The results will be the subject of a poster discussion presentation at the European Society of Medical Oncology 2016 Congress, which is being held October 7-11 in Copenhagen, Denmark. "Cobimetinib and vemurafenib is FDA-approved to treat specific forms of BRAF V600 mutation-positive unresectable or metastatic melanoma and has been associated with significant improvements in progression-free survival, overall survival and objective response rate as compared to vemurafenib alone," said Michael M. Morrissey, Ph.D., president and chief executive officer of Exelixis. "The preliminary results to be presented at the ESMO Congress suggest that adding atezolizumab to the combination regimen is associated both with a manageable safety profile and promising antitumor activity."

EXEL

Exelixis

$13.18

0.06 (0.46%)

RHHBY

Roche

$30.54

-0.29 (-0.94%)

  • 07

    Oct

  • 10

    Oct

  • 10

    Oct

  • 19

    Oct

  • 06

    Nov

  • 10

    Nov

EXEL Exelixis
$13.18

0.06 (0.46%)

09/28/16
LEER
09/28/16
NO CHANGE
LEER
Outperform
Exelixis selloff based on ESMO abstracts overdone, says Leerink
Leerink analyst Michael Schmidt believes Exelixis' selloff following the publication of ESMO poster abstracts is overdone. The analyst notes that abstract includes updated data from a Phase Ib trial evaluating the combination of axitinib with pembrolizumab and appears to have sparked competitive concerns for Exelixis. However, he believes it is highly premature to draw conclusions at this point on the company's Cabometyx' market opportunity or potential in Renal Cell Carcinoma. Schmidt reiterates an Outperform rating on the shares. In afternoon trading, Exelixis' stock has dropped over 15% to $13.12 per share.
09/28/16
LEER
09/28/16
NO CHANGE
LEER
Exelixis selloff overdone, says Leerink
08/22/16
GSCO
08/22/16
NO CHANGE
GSCO
Goldman lists companies to be in focus after Medivation deal
After Pfizer (PFE) announced it has agreed to acquire Medivation (MDVN) for $81.50 per share in cash, Goldman Sachs analyst Salveen Richter said he expects a focus on other commercial small-to-mid-cap cancer companies, including Incyte (INCY), Seattle Genetics (SGEN), ARIAD (ARIA) and Exelixis (EXEL). Also noting that Sanofi (SNY), which was pursuing Medivation, has recently suggested an interest in a rare disease transaction up to potentially as large as $20B, he would expect rare disease companies of that size - such as BioMarin (BMRN), Amicus (FOLD) and Ultragenyx (RARE) - to be in focus as well.
08/04/16
STFL
08/04/16
NO CHANGE
STFL
Exelixis price target raised to $12 from $10 at Stifel
Stifel analyst Stephen Willey raised his price target on Exelixis after the company reported significantly better than expected Cabometyx and residual/off-label Cometriq sales into the newly launched indication of refractory renal cell carcinom. Willey expects the results to improve investors' confidence towards the company's growth outlook, and he says that anticipation of front-line CABOSUN results places a near-term floor on the stock. The analyst keeps a Buy rating on the shares.
RHHBY Roche
$30.54

-0.29 (-0.94%)

09/27/16
PIPR
09/27/16
NO CHANGE
Target $62
PIPR
Neutral
Bristol-Myers price target lowered to $62 from $65 at Piper Jaffray
Piper Jaffray analyst Richard Purkiss lowered his price target for Bristol-Myers Squibb (BMY) to $62 saying he sees the company ceding Opdivo's early-mover advantage in lung cancer to competitors. The analyst expects to see details from Roche's (RHHBY) positive OAK trial of Tecentriq vs. docetaxel in non-small cell lung cancer at the upcoming ESMO meeting. Purkiss also expects to see details from Merck's (MRK) positive KEYNOTE-024 trial of Keytruda. The analyst lowered his post-2016 Opdivo forecasts and reiterates a Neutral rating on Bristol shares.
09/12/16
JEFF
09/12/16
NO CHANGE
Target $57
JEFF
Hold
Jefferies cuts Bristol-Myers price target, upgrades AstraZeneca
Jefferies analyst Jeffrey Holford lowered his price target for Bristol-Myers Squibb (BMY) to $57 from $69 saying the stock is positioned for a "rough mid term ride." The analyst sees a "difficult catalyst" set for Bristol shares with "numerous" upcoming competitor read-outs in non-small cell lung cancer. The market could see worse than expected data from Bristol's CM-026 and CM-568 studies as well as better than expected data from AstraZeneca's (AZN) MYSTIC study and Roche's (RHHBY) Chemo-IO studies in the first half of 2017, Holford tells investors in a research note. He keeps a Hold rating on Bristol and upgraded this morning AstraZeneca to Buy from Hold. Holford prefers Astra for its immunology exposure.
09/07/16
09/07/16
NO CHANGE

BioLineRx partnering with Roche company in cancer therapy research
BioLineRx (BLRX) has entered into a collaboration with Genentech, a member of the Roche (RHHBY) Group, to support several Phase 1b studies investigating BioLineRx's BL-8040 in combination with Atezolizumab, Genentech's anti-PDL1 cancer immunotherapy, in multiple cancer indications. The Phase 1b studies will evaluate the clinical response, safety and tolerability of the combination of these therapies, as well as multiple pharmacodynamic parameters, in hematologic malignancies and solid tumors. Under the agreement, Genentech will sponsor and conduct several Phase 1b trials in multiple solid cancer indications. In addition, BioLineRx will sponsor and conduct a Phase 1b study in acute myeloid leukemia patients. The studies are designed to evaluate the safety and efficacy of the combination of BL-8040 and Atezolizumab. Upon completion of the studies, both parties will have the option to expand the collaboration to include a pivotal registration study. Additional details of the collaboration were not disclosed.
09/01/16
BMOC
09/01/16
NO CHANGE
BMOC
Bristol-Myers has negative read through from Roche data, says BMO Capital
BMO Capital analyst Alex Arfaei says that the positive data on Roche's (RHHBY) TECENTRIQ for second line NSCLC is negative for Bristol-Myers' (BMY) cancer drug, Opdivo. The analyst does not think that TECENTRIQ's results will be superior to that of Opdivo, but he believes that Roche's drug appears to have "a significant" benefit in PD-L1 positive patients." He predicts that Roche's drug could take "meaningful market share, particularly outside of the U.S." The analyst keeps a Market Perform rating on Bristol-Myers.

TODAY'S FREE FLY STORIES

ILG

ILG

$18.88

-0.21 (-1.10%)

15:11
03/01/17
03/01
15:11
03/01/17
15:11
Options
Notable call spread in ILG after earnings were reported yesterday »

Notable call spread in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Mar

  • 15

    Mar

  • 16

    Mar

PRGX

PRGX Global

$6.25

0.45 (7.76%)

15:10
03/01/17
03/01
15:10
03/01/17
15:10
Upgrade
PRGX Global rating change  »

PRGX Global upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PDCE

PDC Energy

$67.59

-4.1 (-5.72%)

15:05
03/01/17
03/01
15:05
03/01/17
15:05
Upgrade
PDC Energy rating change  »

PDC Energy upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

  • 20

    Apr

  • 20

    Apr

JUNO

Juno Therapeutics

$24.04

0.64 (2.74%)

15:05
03/01/17
03/01
15:05
03/01/17
15:05
Options
Juno Therapeutics options imply 11.3% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

  • 01

    Apr

SBGI

Sinclair Broadcast

$39.90

-0.05 (-0.13%)

15:01
03/01/17
03/01
15:01
03/01/17
15:01
Hot Stocks
Sinclair Broadcast acquires Tennis Media Company in up to $14M deal »

Sinclair Broadcast Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

PRGX

PRGX Global

$6.25

0.45 (7.76%)

15:01
03/01/17
03/01
15:01
03/01/17
15:01
Upgrade
PRGX Global rating change  »

PRGX Global upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TXT

Textron

$49.46

2.16 (4.57%)

15:01
03/01/17
03/01
15:01
03/01/17
15:01
Options
Bullish flow in Textron as shares rally »

Bullish flow in Textron…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

NUS

Nu Skin

$49.41

-0.13 (-0.26%)

, EQY

Equity One

$31.20

-0.46 (-1.45%)

14:55
03/01/17
03/01
14:55
03/01/17
14:55
Hot Stocks
Breaking Hot Stocks news story on Nu Skin, Equity One »

Nu Skin to replace Equity…

NUS

Nu Skin

$49.41

-0.13 (-0.26%)

EQY

Equity One

$31.20

-0.46 (-1.45%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

REG

Regency Centers

$69.37

-0.98 (-1.39%)

, ENDP

Endo

$13.65

0.36 (2.71%)

14:55
03/01/17
03/01
14:55
03/01/17
14:55
Hot Stocks
Regency Centers to replace Endo in S&P 500 as of 3/2 open »

Regency Centers (REG) is…

REG

Regency Centers

$69.37

-0.98 (-1.39%)

ENDP

Endo

$13.65

0.36 (2.71%)

EQY

Equity One

$31.20

-0.46 (-1.45%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Mar

  • 14

    Mar

ENDP

Endo

$13.65

0.36 (2.71%)

, REG

Regency Centers

$69.37

-0.98 (-1.39%)

14:55
03/01/17
03/01
14:55
03/01/17
14:55
Hot Stocks
Breaking Hot Stocks news story on Endo, Regency Centers »

Endo to replace Regency…

ENDP

Endo

$13.65

0.36 (2.71%)

REG

Regency Centers

$69.37

-0.98 (-1.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Mar

  • 14

    Mar

XOP

SPDR Oil Exploration and Production Fund

$38.88

1.0201 (2.69%)

14:51
03/01/17
03/01
14:51
03/01/17
14:51
Options
Hefty put spread in SPDR Oil Exploration and Production ETF »

Hefty put spread in SPDR…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MNST

Monster Beverage

$41.44

-0.65 (-1.54%)

14:50
03/01/17
03/01
14:50
03/01/17
14:50
Options
Monster Beverage options imply 9.8% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IPXL

Impax

$14.25

-0.4 (-2.73%)

14:45
03/01/17
03/01
14:45
03/01/17
14:45
Downgrade
Impax rating change  »

Impax downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

  • 06

    Mar

  • 14

    Mar

14:45
03/01/17
03/01
14:45
03/01/17
14:45
General news
Market remains at record levels in afternoon trading »

Stocks remain sharply…

GD

General Dynamics

$192.22

2.41 (1.27%)

14:43
03/01/17
03/01
14:43
03/01/17
14:43
Hot Stocks
General Dynamics boosts dividend to 84c per share, adds 10M shares to buyback »

The board of directors of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

P

Pandora

$12.26

-0.125 (-1.01%)

, SIRI

Sirius XM

$5.09

-0.09 (-1.74%)

14:41
03/01/17
03/01
14:41
03/01/17
14:41
Periodicals
Liberty Media: Pandora is 'great product,' 'way undermonetized,' Bloomberg says »

Sirius XM (SIRI) CEO…

P

Pandora

$12.26

-0.125 (-1.01%)

SIRI

Sirius XM

$5.09

-0.09 (-1.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

  • 06

    Mar

  • 19

    Mar

  • 22

    Mar

  • 23

    Mar

GNW

Genworth

$4.14

0.0501 (1.22%)

14:41
03/01/17
03/01
14:41
03/01/17
14:41
Conference/Events
Genworth to host special shareholder meeting »

Special shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Mar

GD

General Dynamics

$192.08

2.27 (1.20%)

14:40
03/01/17
03/01
14:40
03/01/17
14:40
Hot Stocks
Breaking Hot Stocks news story on General Dynamics »

General Dynamics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$240.20

3.73 (1.58%)

, SPX

S&P 500

$2,399.94

36.3 (1.54%)

14:38
03/01/17
03/01
14:38
03/01/17
14:38
Technical Analysis
S&P 500 crosses 2400 for the first time »

The S&P 500 (SPX) has…

SPY

SPDR S&P 500 ETF Trust

$240.20

3.73 (1.58%)

SPX

S&P 500

$2,399.94

36.3 (1.54%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KAR

KAR Auction

$45.02

0.2 (0.45%)

14:33
03/01/17
03/01
14:33
03/01/17
14:33
Hot Stocks
KAR Auction appoints Howse as Chief Commercial Officer »

KAR Auction Services…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Mar

  • 14

    Mar

  • 15

    Mar

APD

Air Products

$142.94

2.47 (1.76%)

, MPC

Marathon Petroleum

$51.23

1.63 (3.29%)

14:30
03/01/17
03/01
14:30
03/01/17
14:30
Hot Stocks
Air Products says wins additional Marathon Petroleum supply contract »

Air Products (APD)…

APD

Air Products

$142.94

2.47 (1.76%)

MPC

Marathon Petroleum

$51.23

1.63 (3.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

CETX

Cemtrex

$3.54

-0.28 (-7.33%)

14:29
03/01/17
03/01
14:29
03/01/17
14:29
Hot Stocks
Cemtrex announces stock buyback of over 200K shares »

Cemtrex announced today…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDCA

MDC Partners

$8.75

-0.1 (-1.13%)

14:27
03/01/17
03/01
14:27
03/01/17
14:27
Hot Stocks
MDC Partners received subpoena from Department of Justice »

MDC Partners disclosed in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

  • 06

    Mar

BUD

AB InBev

$109.93

0.44 (0.40%)

, KR

Kroger

$32.09

0.285 (0.90%)

14:26
03/01/17
03/01
14:26
03/01/17
14:26
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

BUD

AB InBev

$109.93

0.44 (0.40%)

KR

Kroger

$32.09

0.285 (0.90%)

BURL

Burlington Stores

$87.24

-1.77 (-1.99%)

JOY

Joy Global

$28.20

0.005 (0.02%)

ANF

Abercrombie & Fitch

$11.25

-0.51 (-4.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Mar

  • 02

    Mar

  • 07

    Mar

  • 19

    Mar

14:25
03/01/17
03/01
14:25
03/01/17
14:25
General news
Treasury Action: yields remained elevated »

Treasury Action: yields…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.